A Highly Targeted Patient Population

Pfizer has secured a critical regulatory milestone, receiving FDA approval for its updated COVID-19 vaccine, COMIRNATY LP.8.1. However, the triumph is tempered by significant restrictions that will substantially limit its commercial potential. The authorization, granted on August 27, 2025, marks a stark departure from the broad vaccine rollouts seen during the pandemic era.

The approval comes with a narrow scope of use. The LP.8.1-adapted vaccine is authorized exclusively for two specific groups:
* Read more...